Background: Despite adolescents and young adults being the most frequent users of cannabis, all information on cannabis drug testing interpretation is based on data from adults. Aims: This study aimed to define the time course of urinary 11-nor-9-carboxy-tetrahydrocannabinol (THCCOOH) excretion among 70 adolescent and young adult cannabis users during 1 month of biochemically-verified cannabis abstinence. Methods: Urine specimens were collected at non-abstinent baseline and after 2, 3, 8, 15, 21 and 28 days of abstinence. Specimens were tested for THCCOOH with a 'rapid' immunoassay drug test and a confirmatory assay using liquid chromatography-tandem mass spectrometry, with a 5 ng/mL limit of quantitation. Elimination rate was tested using a population pharmacokinetics model. Results/outcomes: Participants had an average of 26 days of abstinence (SD = 6). Initial creatinine-adjusted THCCOOH concentration (CN-THCCOOH) was 148 ng/mg (SD = 157). Half-life was 2 days (SD = 5), with a 10-day window of detection (estimated range: 4-80 days). At the final timepoint and among those with > 25 days of abstinence (n = 62), 40% (n = 25) had THCCOOH concentrations > 5 ng/mL (i.e. detectable on confirmatory assay) and 19% (n = 12) were 'positive' per federal drug testing guidelines (i.e. values greater than 50 ng/mL on the screening immunoassay and 15 ng/mL on the confirmatory assay). More frequent past month cannabis use was associated with higher baseline CN-THCCOOH concentrations, but not with rate of elimination. Nested five-fold cross-validation suggested high model reliability and predictive validity. Conclusions/interpretation: Findings underscore that, as with adults, detectable cannabinoid metabolites do not necessarily indicate recent use in adolescents and young adults. Algorithms that account for THCCOOH levels, assessed longitudinally and time between specimen collections are best equipped to confirm abstinence. Clinical Trial Registration: NCT03276221; https://clinicaltrials.gov/ct2/show/NCT03276221?term=Randi+Schuster&rank=1
Introduction
Cannabis continues to be among the most frequently used drugs in the USA, with the prevalence of use highest among adolescents and young adults (SAMHSA, 2016) . Cannabis is also the most commonly detected intoxicant, after alcohol, among adolescents at school, in the workplace, during roadside safety evaluations and in drug treatment programs (Arria et al., 2011; O'Malley and Johnston, 2013; Whitehill et al., 2014; Zuccato et al., 2017) . Despite adolescents being the most frequent consumers of cannabis, cannabis drug testing methodology and interpretation is based largely on tests conducted in adult users (Huestis, 2007; Schwilke et al., 2011) . The development of guidance on the interpretation of cannabinoid urine drug test results among adolescents and young adults is critical.
The primary psychoactive constituent of cannabis is ∆9-tetrahydrocannabinol (THC). THC is rapidly metabolized via phase I hydroxylation by hepatic cytrochrome P450 (CYP 450) enzymes, namely CYP2C9, CYP2C19 and CYP3A4 (Bland et al., 2005; Bornheim et al., 1992; Watanabe et al., 2007) , into the psychoactive metabolite 11-hydroxy-THC (11-OH-THC) and subsequently into the non-psychoactive metabolite 11-nor-9-carboxy-THC (THCCOOH) (Elkashef et al., 2008; Gruber et al., 2012; Musshoff and Madea, 2006) . THCCOOH is conjugated with glucuronic acid, and primarily excreted in urine (Desrosiers et al., 2014a; Desrosiers et al., 2014b; Scheidweiler et al., 2016; Wall et al., 1983) .
Although urine is the most commonly used biological matrix for detecting cannabis exposure in drug testing programs, the long Urinary 11-nor-9-carboxytetrahydrocannabinol elimination in adolescent and young adult cannabis users during one month of sustained and biochemically-verified abstinence terminal half-life of the drug complicates the ability to distinguish recent cannabis exposure with residual excretion. Urinary excretion of THCCOOH in controlled laboratory settings has been reported in adult cannabis users for up to 46 days of abstinence (Bergamaschi et al., 2013; Cridland et al., 1983; Dackis et al., 1982; Ellis et al., 1985; Goodwin et al., 2008; Kelly and Jones, 1992; Lowe et al., 2009; Swatek, 1984) . Moreover, case reports of even longer elimination rates in uncontrolled settings have been reported (Westin et al., 2009) . Such long detection times are due to the highly lipophilic nature of THC, resulting in bioaccumulation in adipose tissue (Agurell et al., 1970; Kreuz and Axelrod, 1973) and slow excretion (Johansson et al., 1989) .
Despite preclinical and clinical studies demonstrating that acute and chronic effects of cannabis vary by age (Ehrenreich et al., 1999; Gruber et al., 2012; Quinn et al., 2008; Winward et al., 2014) , little is known about the pharmacokinetic profile of cannabis elimination in adolescents and young adults. The objective of this study was to define the time course of urinary THCCOOH excretion in 70 adolescent and young adult frequent cannabis users, aged 15-25, during 1 month of sustained, biochemically-verified cannabis abstinence. This study aimed to improve understanding of THCCOOH detection times following discontinuation of use in adolescents and young adults with chronic cannabis exposure, which is essential for proper interpretation of drug testing outcomes in the workplace, drug treatment and forensic settings.
Methods
Enrollment for this study occurred between July 2015 and July 2018. Written informed consent was obtained for participants over the age of 18 and written parental consent and participant assent were obtained for individuals under the age of 18. Procedures were approved by the Partners Healthcare Human Subjects Committee.
Study sample
Urine cannabinoid concentrations were determined from nontreatment seeking adolescents and young adults between the ages of 15 and 25 years in an outpatient setting, drawn from a larger Boston-based study on cognition during cannabis abstinence (Schuster et al., 2016 (Schuster et al., , 2018 . Participants were recruited via peer referral, community advertisements and via advertising at a public high school in a northwest Boston suburb. Participants included in this sub-study used cannabis at least weekly and used within 2 days of the baseline visit. Additionally, for statistical model building purposes, all participants provided at least two urine samples while enrolled in the trial with THCCOOH concentrations ⩾ 5 ng/mL.
Abstinence and biochemical verification of abstinence
Participants received an escalating financial incentive schedule (i.e. contingency management) for completing 30 days of continuous cannabis abstinence, and urine samples for THCCOOH were collected at seven study visits over 4 weeks as part of a project assessing cognition and cannabis use (Schuster et al., 2016) . Urine THCCOOH concentrations (ng/mL) were normalized to creatinine (mg/dL) to correct for individual differences in hydration and reduce variability (Lafolie et al., 1991) , yielding a THCCOOH to creatinine concentration ratio at each timepoint (CN-THCCOOH; ng/mg). Residual cannabinoid excretion was differentiated from new cannabis exposure by comparing CN-THCCOOH ratios for all specimen pairs collected ⩾ 48 h apart using the statistical model developed by Schwilke and colleagues (Schwilke et al., 2011) that yields an expected CN-THCCOOH ratio associated with specimen pairs collected at specified time intervals during abstinence. Observed ratios that exceeded this expected value were interpreted as new cannabis use. This study employed a 95% specificity threshold, allowing for a 2.5% false positive rate (i.e. a false interpretation of new cannabis use).
Specimen collection and analysis
Urine specimens were obtained at baseline (pre-abstinence) and, on average, 2, 3, 8, 15, 21 and 28 days after enrollment. Participants provided baseline urine specimens within 2 days of last use, with 20% having used cannabis on the day of their baseline study visit. Specimens were screened with an immunoassay rapid dip drug test (RDDT; Medimpex United Inc.), with specimens exceeding the 50 ng/mL detection limit classified as 'positive' for THCCOOH. All specimens, including those with qualitative negative on the immunoassay RDDT screen, were shipped overnight to Dominion Diagnostics (Kingstown, RI, USA) for confirmatory analysis and THCCOOH quantitation using liquid chromatography-tandem mass spectrometry (LC/MS/MS). Samples underwent chemical (alkali) hydrolysis prior to analysis. The limit of quantitation (LOQ) was 5 ng/mL and the upper limit of linearity was 500 ng/mL. As necessary, serial dilutions were performed on samples with high concentrations to obtain a value within the linear range of the assay (i.e. 5 ng/mL-500 ng/mL). The concentrations of diluted samples were multiplied by the employed dilution factor to obtain the quantitative THCCOOH concentration of the original sample. Per federal drug testing guidelines, specimens were considered 'positive' for THCCOOH when analyte values exceeded both 50 ng/mL on the RDDT immunoassay and 15 ng/mL on the confirmatory LC/MS/MS assay (SAMHSA, 2017) .
Samples were also analyzed for pH level (normal range: 4.5-9.0), specific gravity (normal range: 1.0003-1.035), presence of oxidants (nitrites, chromates, peroxidases, bleach and iodine; LOQ: 200 μg/mL) and creatinine (normal range: 20.0-400 mg/dL). Urine creatinine concentration was determined using the DRI ® Creatinine-Detect assay, which is based on the Jaffe reaction where creatinine concentration was determined colorimetrically (Butler, 1975) .
Assessments
At baseline, demographic (age, sex, race, weight, height) and substance use assessments were collected. The quantity and frequency of past 90-day cannabis use were assessed using a modified Timeline Follow-Back interview (TLFB; Robinson et al., 2014) : a validated and widely used instrument in which the interviewer conducted guided queries using a calendar to ascertain a quantitative estimate of frequency of cannabis use in the 90 days prior to the interview date. Memory aids, including use of key dates as reporting anchors, were used to enhance retrospective recall. A TLFB was also completed at all subsequent visits to approximate amount and quantity of substance exposure between study visits. Participants completed the Cannabis Use Disorder Identification Test -Revised (CUDIT-R; Adamson and Sellman, 2003) , a self-report measure of cannabis dependence symptoms. Scores ⩾ 8 were suggestive of hazardous cannabis use and scores ⩾ 12 were suggestive of probable cannabis use disorder.
Analytic approach
A mixed effect pharmacokinetic (PK) model was fit to the data using an exponential decay model, which allowed estimation of the initial CN-THCCOOH concentration on the day of selfreported last exposure (based on the TLFB interview) and the rate at which CN-THCCOOH was eliminated. Random effects for intercept (i.e. estimated CN-THCCOOH concentration at the time of last exposure) and slope (i.e. rate of elimination) were included in the model. Because sex, body mass index (BMI), race (Caucasian v. non-Caucasian), years of cannabis use and number of cannabisusing days in the past 30 days could influence cannabis clearance rate, these variables were included in the model as covariates. Age and years of cannabis use were moderately correlated (r = 0.6, p < 0.0001), and therefore age was not considered as a separate covariate. However, all effects were unchanged when age replaced years of cannabis use in the models.
All CN-THCCOOH concentrations gleaned from confirmatory assays were included in the PK model, regardless of screening result, with the exception of those samples in which new use was indicated per guidelines set forth by Schwilke and colleagues (Schwilke et al., 2011) . Collected specimens in which new use was detected (n = 15 data points), as well as any specimens collected after the point in which new use was detected, were excluded from analyses. Specimen concentrations prior to the re-initiation of cannabis use were modeled. Additionally, because THCCOOH concentrations below the LOQ (5 ng/mL) could not be determined, a data imputation approach was used in which censored data were replaced with predicted values from applying a basic PK model to individual participants' data, estimated using tobit regression (Amemiya, 1984) to correct for bias due to left censored data. Description of this approach and data imputation results for the 120 samples (27% of the total collected) that fell below the LOQ for THCCOOH are presented in Supplementary Appendix 1. This appendix also notes that, while this imputation approach reduces bias from left-censored data on parameters such as the rate of decay, the model may still underestimate variability in residual noise at the subject-level. The final reported mixed effects PK model was fit to the adjusted data within a Bayesian framework (see Supplementary Appendix 1 for estimation details and justification for the employed statistical approach). Variables were considered statistically significant if posterior p-values were < 0.05.
To avoid over-fitting and to minimize the risk of false positives, we used a nested five-fold cross-validation approach to identify reliable correlates of baseline THCCOOH concentration and decay rate using 56 randomly selected participants (the training sample), and then validated how well these variables correlated with the same outcomes in a holdout sample of 14 participants (Cawley and Talbot, 2010) . This approach was repeated five times such that every participant was part of the test sample once. This two-step validation procedure was repeated 30 times, splitting the data into five new partitions each time. Additional details regarding this cross-validation approach are provided in Supplementary Appendix 1.
Analyses were conducted in R (version 3.4.3; R Core Team, (2018)). Data were prepared using the 'dplyr' package (version 0.7.1; (Wickham et al., 2017) , and the mixed effects PK model was fit using the R package 'brms' (version 2.3.1; (Bürkner, 2017) ). The R code used for the full set of analyses can be found here: https://github.com/rettopnivek/Analyses/tree/master/2018/CAM/ THC_decline_07_06_2018.
Results

Description of participant characteristics
Study participants (n = 70) were 63% male and had a mean age of 20 years (SD = 2; range: 15-25 years). Participants used cannabis on 20 of the prior 30 days (SD = 8; range: 4-30 days), and twice per cannabis-using day (SD = 1; range: 1-10 times). The average age of first cannabis exposure was 15 years (SD = 2; range: 11-21 years), and the mean period of use was 5 years (SD = 2; range: 0.4-14 years). On the day of the baseline study visit, 14 participants used cannabis, 45 participants last used 1 day prior to baseline and 11 participants last used 2 days prior to baseline. See Table 1 for additional participant characteristics.
Description of analyzed urine specimens
Analyses included 442 urine specimens (M = 6 samples per participant, range: 2 to 7). Data were excluded or not available for the following reasons: non-abstinence (15 data points across 6 participants), lost to follow-up (presumed non-abstinent; 8 data points across 3 participants), insufficient volume for assays due to in-transit leakage (2 data points across 2 participants), sample dilutions not performed when concentrations exceeded the linear range of the assay (21 data points across 11 participants), and data collected prior to verified abstinence (2 data points across 2 participants). Table 2 summarizes CN-THCCOOH concentrations and Supplementary Appendix 2 provides CN-THCCOOH concentrations by study visit. Large inter-subject variability was observed in both baseline CN-THCCOOH concentrations and decay rates ( Figure 1 ).
CN-THCCOOH concentrations on the day of last cannabis exposure
On the day of self-reported last cannabis exposure, the estimated CN-THCCOOH concentration was 148 ng/mg (SD = 157 ng/mg; range: 22-1929 ng/mg). Frequency of past month cannabis use predicted baseline urine CN-THCCOOH concentration, with more frequent users having higher concentrations (β Frequency = 0.5, p < 0.001). In contrast, sex, BMI, race and years of cannabis use were not associated with baseline CN-THCCOOH concentration (i.e. β sex = 0.02, p = 0.4, β BMI = -0.1, p = 0.12, β race = -0.05, p = 0.27 and β years = 0.03, p =0.35).
Rate of CN-THCCOOH decay across 30 days of abstinence
Participants had an average of 27 days of continuous cannabis abstinence (SD = 6; range: 2-34 days) from the estimated day of last cannabis use ( Table 2 ). The estimated half-life of CN-THCCOOH was 2.4 days (SD = 5 days). The estimated window of urinary CN-THCCOOH detection (i.e. the number of days before THCCOOH concentration dropped below the LOQ of 5 ng/mL) was 10 days (95% CI: 8-13 days; 95% prediction interval: 4-80 days; Figure 2 ). At the final measurement timepoint, among the 62 participants with at least 25 days of self-reported and biochemically-verified cannabis abstinence, 25 (40%) had detectable THCCOOH concentrations (i.e. > 5 ng/mL) and 12 (19%) had both THCCOOH concentrations ⩾ 15 ng/mL on LC/MS/MS and ⩾ 50 ng/mL on immunoassay, thus would be considered to have a 'true positive' test for cannabis exposure by current federal drug testing convention.
Estimated initial CN-THCCOOH concentration was correlated with decay rate (r = 0.35, p = 0.002), with higher CN-THCCOOH baseline urine concentrations associated with longer elimination rates. Sex, BMI, race, years of cannabis use and frequency of past month cannabis use were not significantly associated with decay rate (i.e. β sex = 0.01, p = 0.42, β BMI = 0.05, p = 0.15, β race = 0.02, p = 0.31, β years = -0.03, p = 0.23 and β frequency = 0.07, p = 0.05).
PK model validation
In 5-fold cross-validation with 30 repetitions, the null model was preferred in 13% of repetitions, while the predictive models were Change in CN-THCCOOH (a) and the log of CN-THCCOOH (b) over days since last cannabis exposure for four representative subjects. Filled points refer to two subjects with low starting concentrations of CN-THCCOOH, while empty points refer to two subjects with high starting concentrations of CN-THCCOOH. The triangular symbols refer to two subjects with rapid elimination rates, while the square and diamond symbols refer to two subjects with slow elimination rates. (THCCOOH: 11-nor-9-carboxy-tetrahydrocannabinol; CN-THCCOOH: creatinine-adjusted THCCOOH.) Figure 2 . Raw and estimated change in CN-THCCOOH levels across 30 days of cannabis abstinence.
Change in CN-THCCOOH (a) and the log of CN-THCCOOH (b) over days since last cannabis exposure. Gray points represent the observations for individual participants. Triangles (in (b)) represent values that fell below the limit of quantitation (LOQ; approximated by the dashed line) and were estimated via imputation. Diamonds connected by a line represent mean CN-THCCOOH concentration per day for values above the LOQ, which yielded a variable and potentially biased estimate of the rate of decay during abstinence due to missing data. The solid black line depicts the estimated decline in CN-THCCOOH in the population based on the pharmacokinetic model, which controls for individual differences in CN-THCCOOH levels and missing data. (CN-THCCOOH: creatinine-adjusted 11-nor-9-carboxy-tetrahydrocannabinol; LOQ: limit of quantitation.) preferred 87% of the time. Frequency of cannabis use predicted baseline CN-THCCOOH concentrations in 80% of the predictive models and, in fact, was the only significant predictor 80% of the time. Over the 5 folds and 30 repetitions, 95% predictive coverage intervals for the best-fitting model captured the withheld sample of 14 subjects 98% of the time (range: 85-100%), suggesting good model performance. Furthermore, the best-fitting models captured an average of 33% of the variance in CN-THCCOOH (range: 12-61%).
Discussion
This study aimed to replicate prior research on the rate of elimination of THCCOOH and extend findings to adolescents and young adults, a relevant subpopulation given the disproportionate heavy rates of use and prevalence of adverse consequences in this age group. An elimination pattern comparable to that reported in prior studies of adults was observed (Huestis and Cone, 1998; Kelly and Jones, 1992) , with a rapid decrease in THCCOOH levels during the first 3 days of abstinence followed by a more gradual decrease during subsequent days.
THCCOOH in adolescents and young adults was estimated to have a half-life of approximately 2 days, with an average window of detection of 10 days. Importantly, after 1 month of abstinence, 40% of participants still had detectable urine CN-THCCOOH levels and 20% would have been classified as 'positive' per federal drug testing guidelines. Findings are consistent with studies in adults that find a mean urinary excretion half-life of approximately 2 days with gas chromatography-mass spectrometry monitoring of THCCOOH for 12-14 days (Huestis and Cone, 1998; Kelly and Jones, 1992) . Although future studies are needed that directly compare elimination rates in older and younger cohorts, age was not predictive of THCCOOH decay rate in the current study. Thus, the hypothesis is raised that the well-documented association between earlier age of cannabis use and greater adverse consequences (Fischer et al., 2017) is unlikely to be mediated through more protracted exposure to circulating THCCOOH. However, as has been demonstrated with other substances (e.g. Rubinstein et al., 2008; Sofuoglu et al., 2012) , this hypothesis needs to be directly tested using studies that evaluate blood or plasma concentrations of THC and its active and inactive metabolites in the days to weeks after cessation of use. Such studies will be ideally positioned to examine whether the magnitude and persistence of cannabinoid presence are associated with withdrawal, susceptibility for cannabis use disorder and resolution of residual neurocognitive impairment, as well as whether these associations vary by age or age of first cannabis exposure.
Despite all participants having used within 2 days of their baseline visit, substantial variability in both quantitative baseline CN-THCCOOH concentrations and rates of elimination were observed, as evidenced by a predicted window of detection ranging from 4 to 80 days. There was no evidence in this sample that sex, BMI, race, years of cannabis use, or frequency of baseline cannabis use impacted rate of elimination. While other studies have found a longer elimination half-life in daily or near-daily cannabis users compared with occasional users (e.g. (Toennes et al., 2008) , this study suggests that frequency of use among adolescent and young adult cannabis users is not a direct correlate of the rate of elimination. Current findings contrast prior reports of higher BMI associated with a longer window of THCCOOH detection (Goodwin et al., 2008) . The wider BMI range of 19.5-42.5 and higher mean BMI of 25.4 in the study by Goodwin and colleagues (Goodwin et al., 2008) , compared to the current study, in which no participants fell into the obese range (mean BMI = 22.9; range: 16.9-29.6), may have conferred greater sensitivity for detecting association of BMI with THCCOOH elimination rate. It is also possible that BMI, as measured in the current study, was not the most reliable surrogate measure of adiposity in adolescents. Future studies should consider other factors not examined in the current study as potential moderators of variability in THCCOOH elimination rate. For example, other studies have found conditions that potentiate lipolysis, such as food deprivation, exercise and stress, modestly increase THC release from adipose tissue (Gunasekaran et al., 2009; Westin et al., 2014; Wong et al., 2013) . Additionally, as THC is predominantly hepatically metabolized via cytochrome P450 (CYP 450) isozymes CYP2C9, CYP2C19 and CYP3A4 (Bland et al., 2005; Huestis, 2007; Schwope et al., 2011; Stott et al., 2013; Watanabe et al., 2007) , genes and other exogeneous substances that modulate the induction and/or inhibition of these enzymes may alter the pharmacokinetics of THC and its downstream metabolites (Sachse-Seeboth et al., 2009 ). Lastly, this study found initial THCCOOH concentration to be correlated with elimination rate, and therefore future investigations should consider factors that dictate initial THC burden, including disease states that influence the permeability of blood-tissue barriers (Lucas et al., 2018) , cannabis potency (Lucas et al., 2018; Zendulka et al., 2016) and method of consumption (e.g. ingested v. vaporized v. smoked).
Most previous work looked at windows of THCCOOH detection as defined by the time of last positive screen and/or first negative screen on binary urinary drug tests (e.g. Goodwin et al., 2008) . Use of binary detection windows fails to consider the dual influence of both starting THCCOOH concentration and its halflife on the time course of elimination. For example, two individuals may have comparable times to last positive screen and/or first negative screen on binary urinary drug tests, but this may be attributable to either of the following plausible scenarios: (a) participant A has a higher starting THCCOOH concentration but a faster rate of elimination than participant B; (b) participant A and B have comparable starting values and rates of elimination. In the present study, initial normalized THCCOOH concentration did not correlate with half-life, further underscoring possible conflation of the two parameters into one estimate of time course of elimination. The PK model used in the current study relies on a non-linear function of both initial THCCOOH concentration and half-life to more accurately estimate the time course of THCCOOH elimination. Use of the PK model will allow future studies to identify predictors associated with only starting concentration or elimination rate.
Generality of findings should be considered in the context of the following limitations. First, although our goal was to obtain seven specimens from each participant collected 7 days apart (aside from the first week of the study), the number of specimens collected per participant ranged from two to seven, and the days between collection varied. Although these sources of variability were corrected for by the mixed-effects aspect of the PK model, future studies that collect more specimens per individual will benefit from reduced uncertainty at the subject-level around both starting levels and elimination rates. Second, there were 21 samples that were excluded from analyses because concentrations exceeded the linear range of the assay but dilutions were not performed. Although this only accounts for 4% of the total samples collected, more accurate quantifications for these samples may have improved the prediction data. Third, this study did not consider elimination rates of other cannabinoids (e.g. cannabidiol) as well as other THC metabolites (e.g. 11-OH-THC). Fourth, participants were not required to abstain from other substance use during the 30-day cannabis abstinence protocol, and it is not known how fluctuations in other substance exposure impacts elimination rates (Anderson and Chan, 2016; Dube et al., 2015) . Relatedly, due to a low overall endorsement of use, analyses did not control for concomitant prescription drug use and drug-drug interactions cannot be overlooked in this outpatient study.
Additional statistical limitations are also worth discussing. The method used to biochemically confirm sustained cannabis abstinence was developed for daily users (Schwilke et al., 2011) , and participants in the present study were required to use at least weekly (51.6% used ⩾ 5 days per week). This discordance in sample characteristics has the potential to result in error rates that are not properly calibrated with those observed by Schwilke and colleagues. However, use of the PK model allows for a conservative approximation of abstinence because any individual for whom exponential decay was not evident would be detected and dropped from analyses, even if no new use was indicated per the Schwilke algorithm. It should be noted that no mismatch between the Schwilke algorithm and results from the PK model were found in the current study of at least weekly cannabis users. Second, frequency of past 90-day cannabis use and time of last cannabis exposure were based on self-report during a TLFB interview. Although this interview has sound psychometric properties and employs techniques to enhance recall (e.g. use of a calendar and memory aids), inaccuracies inherent to retrospective recall remain possible and contribute to the residual noise in the model and measurement error in our predictions. Relatedly, the PK model was used to extrapolate CN-THCCOOH levels on the self-reported day of last use, occasionally resulting in cases in which the estimated level of CN-THCCOOH at last use fell below the observed value at the first baseline measurement due to measurement error. Future work should aim to enroll participants on or before the day of last use to more precisely quantify THCCOOH concentration soon after last exposure, providing a more accurate baseline measurement and minimizing measurement error. Third, the population-level PK model tends to predict lower initial THCCOOH concentrations compared to the average. Difficulty predicting extremely high initial THCCOOH concentrations for a small subset of subjects is most likely attributable to 'shrinkage', an inherent characteristic of multilevel models, in which the model introduces some degree of misfit in subjectlevel estimates (especially for extreme values) shrinking them towards the population-level estimates. Finally, nearly one quarter of the collected specimens had THCCOOH concentrations that fell below the limit of quantitation; assays with a 2.5 or 1 ng/ mL cutoff would have enabled more specimens to be included in the model. We employed a data imputation approach to minimize this loss of information and resolve bias due to left-censored data. However, this approach can still underestimate variability in residual noise. Future research should explore improved methodology, specifically extensions with either (a) multiple imputation approaches, or (b) fully hierarchical tobit regression approaches for PK modeling.
To our knowledge, this is the largest study in terms of number of enrolled participants of THCCOOH elimination and the first to be reported using adolescents. Findings support the use of a population PK model to estimate the half-life of cannabinoids. Further, findings implicate long windows of detection that may result in substantial urinary THCCOOH concentrations even after 1 month of abstinence, as well as significant variability in baseline THCCOOH levels and elimination rates. Therefore, algorithms that account for quantitated levels of THCCOOH assessed longitudinally, creatinine and time between specimen collections are best equipped to biochemically confirm abstinence. Findings desperately call for novel assays that can be administered at single timepoints that can detect recent cannabis exposure and intoxication in both adults and adolescents.
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